The fact
The company adds a new first-in-class monoclonal antibody, FPR2 agonist, to its therapeutic portfolio.
This strategic expansion aims to strengthen its presence in oncology immunotherapy.
Click the link to read an article on the topic:
The company adds a new first-in-class monoclonal antibody, FPR2 agonist, to its therapeutic portfolio.
This strategic expansion aims to strengthen its presence in oncology immunotherapy.